Actualités Insys Therapeutics, Inc. - INSY | Actions NASDAQ

Outils de qualité professionnelle, pour des investisseurs individuels.

Premium

Notification Filed by National Security Exchange to Report the Removal From Listing and Registration of Matured, Redeemed or ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM...

INSYS Therapeutics, Inc. Receives Court Approval of “First Day” Motions

PHOENIX, June 12, 2019 (GLOBE NEWSWIRE) -- INSYS Therapeutics, Inc. (NASDAQ: INSY) (“INSYS” or the...

Current Report Filing (8-k)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON...

Current Report Filing (8-k)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON...

INSYS Therapeutics Initiates Court-Supervised Process to Facilitate Asset Sales and Address Legacy Liabilities

Company to Facilitate Transaction Process and Sale of Substantially All Assets Through Chapter 11 of the U.S...

Amended Current Report Filing (8-k/a)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON...

Statement of Changes in Beneficial Ownership (4)

FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may...

Initial Statement of Beneficial Ownership (3)

FORM 3 UNITED STATES SECURITIES AND EXCHANGE...

Current Report Filing (8-k)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON...

Statement of Changes in Beneficial Ownership (4)

FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may...

Current Report Filing (8-k)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON...

Notification That Quarterly Report Will Be Submitted Late (nt 10-q)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C...

Current Report Filing (8-k)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON...

Quarterly Report (10-q)

Table of Contents FYI UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington...

INSYS Therapeutics Reports First Quarter 2019 Results

Company Continues to Execute Against Pipeline-Focused StrategyNew Drug Application Submitted for Proprietary...

Forums

Afficher les forums

Aucune Discussion Trouvée

Ajouter une Discussion

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Insys Therapeutics, Inc. (INSY)

Outils de qualité professionnelle, pour des investisseurs individuels.

INSY Actualités

Notification Filed by National Security Exchange to Report the Removal From Listing and Registration of Matured, Redeemed or ...

INSYS Therapeutics, Inc. Receives Court Approval of “First Day” Motions

Current Report Filing (8-k)

Current Report Filing (8-k)

INSYS Therapeutics Initiates Court-Supervised Process to Facilitate Asset Sales and Address Legacy Liabilities

Amended Current Report Filing (8-k/a)

Statement of Changes in Beneficial Ownership (4)

Initial Statement of Beneficial Ownership (3)

Current Report Filing (8-k)

Statement of Changes in Beneficial Ownership (4)

Current Report Filing (8-k)

Notification That Quarterly Report Will Be Submitted Late (nt 10-q)

Current Report Filing (8-k)

Quarterly Report (10-q)

INSYS Therapeutics Reports First Quarter 2019 Results

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Insys Therapeutics, Inc. (INSY) Actualités

Insys Therapeutics, Inc. (INSY)

Outils de qualité professionnelle, pour des investisseurs individuels.

INSY Actualités

Notification Filed by National Security Exchange to Report the Removal From Listing and Registration of Matured, Redeemed or ...

INSYS Therapeutics, Inc. Receives Court Approval of “First Day” Motions

Current Report Filing (8-k)

Current Report Filing (8-k)

INSYS Therapeutics Initiates Court-Supervised Process to Facilitate Asset Sales and Address Legacy Liabilities

Amended Current Report Filing (8-k/a)

Statement of Changes in Beneficial Ownership (4)

Initial Statement of Beneficial Ownership (3)

Current Report Filing (8-k)

Statement of Changes in Beneficial Ownership (4)

Current Report Filing (8-k)

Notification That Quarterly Report Will Be Submitted Late (nt 10-q)

Current Report Filing (8-k)

Quarterly Report (10-q)

INSYS Therapeutics Reports First Quarter 2019 Results

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Supprimer les publicités